Evolus

EOLS · NASDAQ

$7.37+$0.01 (+0.14%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $7.36

Latest news

Press releaseOct 20, 4:13 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Press releaseOct 15, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Press releaseOct 14, 8:30 AM ETBusiness Wire
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
Press releaseOct 12, 2:46 PM ETBusiness Wire
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
Press releaseOct 8, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Press releaseOct 6, 7:20 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
NewsOct 2, 1:47 PM ETVandana Singh
Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug
Press releaseOct 1, 8:30 AM ETBusiness Wire
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
Press releaseSep 1, 11:37 AM ETPRNewswire
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
Press releaseAug 31, 6:21 PM ETGlobe Newswire
Telix Appoints David Gill as Chair
Press releaseAug 5, 4:05 PM ETBusiness Wire
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
Press releaseAug 4, 8:30 AM ETBusiness Wire
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
Press releaseJul 22, 8:30 AM ETBusiness Wire
Evolus to Report Second Quarter Financial Results on August 5, 2026
Press releaseJul 10, 4:05 PM ETBusiness Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJul 9, 8:16 AM ETPRNewswire
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
Press releaseJul 8, 9:00 AM ETBusiness Wire
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Press releaseMay 22, 10:31 AM ETPRNewswire
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
Press releaseMay 19, 8:30 AM ETBusiness Wire
Evolus to Participate in The Jefferies Global Healthcare Conference
Press releaseMay 11, 8:30 AM ETBusiness Wire
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
Press releaseMay 4, 4:05 PM ETBusiness Wire
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
NewsMay 4, 8:02 AM ETAvi Kapoor
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
NewsMay 4, 7:11 AM ET
Earnings Scheduled For May 4, 2026
Press releaseApr 14, 8:30 AM ETBusiness Wire
Evolus to Report First Quarter Financial Results on May 4, 2026
Press releaseApr 1, 7:53 PM ETGlobe Newswire
Telix Appoints David Gill as Non-Executive Director
Press releaseMar 31, 8:00 AM ETBusiness Wire
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
Press releaseMar 20, 4:05 PM ETBusiness Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsMar 4, 12:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsMar 4, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsMar 3, 4:54 PM ET
Evolus Q4 Earnings Summary & Key Takeaways
NewsMar 3, 4:52 PM ET
CORRECTION: Evolus Q4 Adj. EPS $0.05, Inline, Sales $90.300M Beat $89.667M Estimate
NewsMar 3, 4:08 PM ET
Evolus: Q4 Earnings Insights
Press releaseMar 3, 4:05 PM ETBusiness Wire
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026
NewsMar 3, 6:11 AM ET
Earnings Scheduled For March 3, 2026
NewsMar 2, 12:02 PM ET
What to Expect from Evolus's Earnings
Press releaseFeb 25, 8:00 AM ETBusiness Wire
Evolus to Participate in The Leerink Partners Global Healthcare Conference
Press releaseFeb 17, 8:00 AM ETBusiness Wire
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
NewsNov 6, 7:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsAug 6, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsAug 6, 8:08 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program

EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug

Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes

A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture

Telix Appoints David Gill as Chair

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

Evolus to Report Second Quarter Financial Results on August 5, 2026

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

Evolus to Participate in The Jefferies Global Healthcare Conference

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Earnings Scheduled For May 4, 2026

Evolus to Report First Quarter Financial Results on May 4, 2026

Telix Appoints David Gill as Non-Executive Director

Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Evolus Q4 Earnings Summary & Key Takeaways

CORRECTION: Evolus Q4 Adj. EPS $0.05, Inline, Sales $90.300M Beat $89.667M Estimate

Evolus: Q4 Earnings Insights

Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

Earnings Scheduled For March 3, 2026

What to Expect from Evolus's Earnings

Evolus to Participate in The Leerink Partners Global Healthcare Conference

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session